WASHINGTON – Sens. Chuck Grassley
(R-Iowa), Joe Manchin (D-W.Va.), Joni Ernst (R-Iowa) and John Kennedy (R-La.)
are
pressing the Federal Trade Commission (FTC) and the Horseracing Integrity and
Safety Authority (the Authority) for answers on its implementation and
enforcement of certain guidelines under the
Horseracing Integrity and Safety
Act (HISA). Specifically, the senators draw attention to the Anti-Doping
and Medication Control program, which
HISA requires to be implemented by
July 1, 2022. However, the Authority has already stated it would not meet that
deadline.
“HISA required the Authority to issue the
rule for Anti-Doping and Medication Control not later than 120 days before the
program effective date of July 1, 2022. This deadline has passed, and it
appears the Authority failed to meet the statutory requirements. The FTC
requires the Authority to submit any proposed rule at least 90 days before the
proposed rule is to be published in the Federal Register for public comment. We
are also not aware of any request or approval of a waiver of this requirement,”
the lawmakers wrote.
Additionally, the senators raise concerns
about new rules regarding horseshoes and riding crop specifications – initially
set to take effect on July 1 under the Racetrack Safety Program – that were
impossible for industry stakeholders to implement due to supply chain issues.
“This chaotic implementation process and
poor communication by the Authority makes it difficult for industry
participants to comply with the new rules and regulations. Additionally,
continuously changing implementation dates for new rules and regulations, and
last minute delays, cause more confusion and difficulty with implementation,” the lawmakers continued.
Grassley, Manchin, Ernst and Kennedy
further argue that the Authority’s haphazard approach to setting fee structures
will leave racetracks “without the certainty and transparency they need to
budget for the current and future racing seasons.”
In conclusion, the senators ask the FTC
and the Authority to explain why the July 1 deadline to implement the
Anti-Doping and Medication Control Program will not be met, answer for their
failure to issue a rule prior to the date required by HISA and clarify whether experts and stakeholders were consulted in
the initial drafting of these rules.
Full text of the letter is available
HERE.
-30-